gemcitabine

P1, N=6, Terminated, HonorHealth Research Institute | Trial completion date: Dec 2026 --> Dec 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Jun 2026 --> Dec 2025; The study was terminated early per the recommendation of the Data and Safety Monitoring Board (DSMB) after a planned interim analysis met pre-specified criteria for futility.

Additionally, combination of Bru with Cis or Gem significantly reduced colony formation, and suppressed cell migration and invasion in KKU-100 cells. These findings support the potential of Bru as a promising anti-cancer agent or adjunct therapy to enhance current chemotherapy in CCA treatment.

P=N/A, N=30, Recruiting, M.D. Anderson Cancer Center

P2, N=29, Recruiting, Sabine Mueller, MD, PhD | Not yet recruiting --> Recruiting

Patients received treatment according to the institutional protocols in the form of RCHOP [rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone] and RDHAP [rituximab, dexamethasone, high dose cytarabine and cisplatin] as induction therapy and ICE [ifosfamide, carboplatin, etoposide], ESHAP [etoposide, methylprednisolone, high dose cytarabine and cisplatin], gemcitabine-based protocols, and others as second line therapies. To overcome the limitations in our study, larger cohorts are needed to be studied with the evaluation of the novel therapies when feasible. Enhancing financial support is crucial to improve MCL patients' care in our country.

P2/3, N=10, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting

Although gemcitabine-based regimens remain widely utilized, the molecular pathways that influence treatment-associated biological variation are incompletely understood...Conversely, genomic alterations within the JAK/STAT pathway are uncommon, indicating that pathway activity may be regulated predominantly through non-genomic mechanisms. These findings demonstrate the utility of conversational artificial intelligence agents for rapid, scalable, and clinically contextualized pathway interrogation and support future studies integrating multi-omic data to refine precision medicine strategies in PDAC.

The alkylating chemotherapeutic agent cyclophosphamide (CTX) has direct tumoricidal and immunomodulatory properties, including the induction of homeostatic proliferation of T cells...These effects extended to other lymphodepleting treatments, such as gemcitabine and radiation therapy...Furthermore, combined CTX and αPD-1+αCTLA-4 treatment demonstrated efficacy across additional preclinical tumor models, including colorectal cancer and triple negative breast cancer. Overall, these findings highlight that the combination of CTX and ICB represents a clinically relevant approach in the treatment of immunotherapy-refractory tumors.

P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> May 2027

In vivo, GEM inhibited tumor growth and downregulated HIF1A, UBR5, and FGFR1. GEM suppresses OC progression by targeting the HIF1A/UBR5 axis, which subsequently stabilizes LATS2, activates the Hippo pathway, and inhibits YAP1/FGFR1 signaling, revealing a novel therapeutic mechanism.

Chemosensitivity to gemcitabine and 5-fluorouracil (5-FU) was also evaluated. Knockdown of COLEC12 increased the sensitivity of PC cells to gemcitabine and 5‑FU. This study reveals, for the first time, the tumor-promoting function of COLEC12 in PC and highlights its potential as a therapeutic target in PC.

P1, N=102, Completed, Genentech, Inc. | Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Mar 2026